Corresponding Author: Edward A. Nardell, MD, Brigham and Women’s Hospital, Division of Global Health Equity, Harvard Medical School, 75 Francis St, Boston, MA 02115 (email@example.com).
Published Online: June 1, 2020. doi:10.1001/jama.2020.7603
Conflict of Interest Disclosures: Dr Nardell has been supported entirely by research and implementation grants from the National Institutes of Health (NIH) and the United States Agency for International Development (USAID). Relevant to this commentary, Dr Nardell has consulted on a voluntary basis with the World Health Organization, USAID, Illuminating Engineering Society, and the National Academies of Sciences, Engineering, and Medicine. He has not served as a paid consultant and has no current or past commercial interest in any air disinfection technologies or related products. Dr Nathavitharana reports receipt of grants from NIH and the National Institute of Allergy and Infectious Diseases.
HV . Rapid Expert Consultation on SARS-CoV-2 Viral Shedding and Antibody Response for the COVID-19 Pandemic (April 8, 2020). National Academies of Science, Engineering, and Medicine; 2020.
M , Dharmadhikari
AS , Jensen
et al. Institutional tuberculosis transmission controlled trial of upper room ultraviolet air disinfection: a basis for new dosing guidelines. Am J Respir Crit Care Med
. 2015;192(4):477-484. doi:10.1164/rccm.201501-0060OCPubMedGoogle ScholarCrossref